COMPARTMENTAL PHARMACOKINETIC ANALYSIS OF ORAL AMPRENAVIR WITH SECONDARY PEAKS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，不一定是研究者的机构。 安普那韦是一种蛋白酶抑制剂，已被证明具有推测是由于肝肠循环的次级峰。我们提出了一个模型来描述安普那韦的药代动力学，其中包括第二峰。作为成人艾滋病临床试验组方案A5043的一部分，共有82例健康的人类免疫缺陷病毒（HIV）血清阴性受试者接受单次600 mg安普那韦给药。在24小时内获得系列血液样品。分析样品中的安普那韦，并使用ADAPT II软件拟合房室模型，所有相关参数均以生物利用度为条件。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Amprenavir is a protease inhibitor that has been shown to have secondary peaks postulated to be due to enterohepatic recycling. We propose a model to describe the pharmacokinetics of amprenavir which accommodates the secondary peak(s). A total of 82 healthy human immunodeficiency virus (HIV)-seronegative subjects were administered a single 600-mg dose of amprenavir as part of adult AIDS Clinical Trials Group protocol A5043. Serial blood samples were obtained over 24 h. Samples were analyzed for amprenavir and fit to a compartmental model using ADAPT II software, with all relevant parameters conditional with respect to bioavailability.